The doctor wasn't making a clinical decision. He was making a financial one.
That's the argument Dr. Roland Flores, an anesthesiologist and acute pain specialist, brought to the Colorado Senate Health & Human Services Committee on April 8, 2026. His message was blunt: the reason opioids flow so freely through American medicine isn't because doctors prefer them. It's because insurance companies made them cheaper and easier to prescribe than the alternatives.
"We've built a system where the most addictive pain medications are sometimes the easiest ones to prescribe," Flores told the committee. "And it's not a clinical decision. That's a coverage design problem."
That testimony kicked off two days of hearings that, taken together, reveal how Colorado is quietly — and in some cases controversially — trying to fix a health care system fraying at nearly every edge. Opioid overuse. Kidney disease going undetected. Mental health patients falling through the cracks after holds. Compounding pharmacies caught in a legal crossfire. A rural psychiatric unit that can't get Medicaid to recognize it exists. In April 2026, Colorado lawmakers took on all of it.
The Opioid Problem Is a Paperwork Problem
Senator Mike Weissman didn't mince words when CDC dispensing data landed in front of the committee during the debate on SB 26-006, a bill that would require insurers to treat non-opioid pain drugs at least as favorably as opioids — no more restrictive prior authorizations, no worse cost-sharing.
"35.4 per 100 people is 120 million opioid scripts in this country in 2024," Weissman said. "That strikes me as completely insane. And honestly, it makes me want to throw up. Like, have we learned nothing?"
The bill's core insight is almost perversely simple: if you want doctors to prescribe fewer opioids, stop making opioids the path of least resistance. Under current insurance design, a physician in an emergency room might find that IV opioids are instantly covered while a non-opioid alternative requires prior authorization, step therapy, or a higher co-pay. The clinical calculus gets distorted by the financial one.
SB 26-006's prime sponsor, Senator Barbara Kirkmeyer, and her colleagues secured a 6-1 committee vote to advance the bill to the Committee on Appropriations — but not before stripping out two of its most important coverage populations. Amendments L001 and L004, passed over the sole objection of committee chair Senator Kyle Mullica, removed Medicaid patients and the state plan from the bill's reach entirely. The reason: budget constraints in a tight fiscal year.
Kirkmeyer was candid about the compromise. "We don't like the amendment but we need it because of the budget year we're in," she told the committee, "and these are the difficult choices that we've been making for the last, I don't know, six, seven months."
Mullica's frustration was pointed. The chair argued it was "difficult" to hear that the bill was important enough to mandate for private insurers but not for the Medicaid patients who often have the least leverage and the fewest alternatives. The optic, he said, was problematic — though he was outvoted 6-1.
Opponents from the pharmacy benefits industry argued the bill essentially creates a mandate for a monopoly product. Patrick Boyle of the Pharmacy Care Management Association warned that Journavx — currently the only FDA-approved non-opioid pain drug that would qualify under the bill — could raise its prices "indefinitely" without competitive pressure. Kirkmeyer pushed back, citing four companies already offering non-opioid alternatives with eight more in Phase 3 trials. The committee sided with the sponsors.
One in Seven Adults. Ninety Percent Don't Know.
The kidney disease bill — HB 26-1019 — passed the committee unanimously, 7-0, but the numbers Senator Dylan Roberts cited in its support were startling enough to deserve their own reckoning.
According to Roberts, one in seven adults has chronic kidney disease — but 90 percent of them don't know it. In Colorado alone, Roberts cited figures showing more than 8,000 residents are treated for end-stage renal disease, nearly 5,000 rely on dialysis, and the disease costs an estimated $457 million annually statewide, with patients paying nearly $58 million out of pocket. An actuarial analysis cited by Roberts pegged the cost of universal annual kidney screening at just $0.01 to $0.04 per member per month — a fraction of a penny — to prevent or catch early a disease that, left undetected, becomes catastrophically expensive to treat.
HB 26-1019 would require insurance plans to cover that annual kidney function screening as a preventive service at no cost to patients. Chair Mullica expressed disappointment that, once again, fiscal constraints forced the bill's sponsors to exclude state employee health plans. Senator Roberts kept the bill off the consent calendar, citing a pending federal regulation that could require amendments before it reaches the Senate floor.
The bill's backstory adds texture. On April 9, a private citizen named Chris Schwab testified in support of the related HB 26-1280, which extends regulation of hemodialysis treatment clinics for another 11 years. Schwab told the committee his daughter deals with kidney disease — and that he was part of the group that got the original hemodialysis regulation bill through the state House back in 2007. Nearly two decades later, he's still showing up. The committee passed that bill unanimously.
The Forty-Eight-Hour Gap
For people who've worked in mental health crisis intervention, the hours immediately after a psychiatric hold aren't a bureaucratic afterthought. They're the moment everything can go wrong.
Senator Ball, who co-sponsored HB 26-1116, drew on that experience directly. "I used to do a lot of work with individuals who were placed under mental health holds and the follow ups are really, really important," he told the committee. "A lot of times what happens is you have a mental health hold that lasts for as short as two or three hours, as long as 24 hours. But if you don't have that follow up immediately after, it's really easy to lose people."
The bill extends the post-hold follow-up window from 48 to 72 hours — an adjustment that, on its face, sounds minor. But Audrey Hinshaw of UC Health and the Colorado Hospital Association explained the operational reality: hospitals were being held to a 48-hour follow-up standard while other programs used a three-day window, creating confusion for care teams coordinating across the system. Aligning the windows reduces the chance that a patient discharged from one setting falls into the gap between different providers' timelines.
Amy Hickson, Quality and Standards Division Director at the Behavioral Health Administration, added a structural concern that went beyond the follow-up window. Under current licensing rules, she testified, the compliance burden is so heavy that "in person outpatient providers" risk "limiting their physical locations or switching exclusively to telehealth just to streamline their licensing process or reduce cost" — a dynamic that would quietly shrink the behavioral health network available to patients who can't or won't do telehealth. HB 26-1116 adjusts those fire inspection certificate requirements for telehealth and outpatient-only providers. It passed 6-0.
The Psychiatric Unit That Didn't Officially Exist
In Edwards, Colorado — a town tucked into Eagle County along I-70, 14 miles west of Vail — Vail Health opened a 28-bed inpatient psychiatric facility called the Pre Court Healing Center. It serves patients from across Colorado. By Will Cook's telling, it is the only inpatient behavioral health facility between Denver and Salt Lake City.
There's just one problem. Because the facility isn't physically attached to the main Vail Health campus in Vail, Colorado Medicaid wouldn't recognize it as part of the hospital — meaning it couldn't bill Medicaid as a hospital-based unit. The financial consequences were severe: Cook testified that doing it separately without a legislative fix would cost at least $2 million in extra startup costs and about a million dollars in ongoing annual expense, with — as Chief Strategy Officer Nico Brown put it — "zero impact on patients."
HB 26-1305 fixes that with a narrow statutory clarification: an inpatient psychiatric facility can be considered part of a hospital campus for licensing and Medicaid purposes even if it's not physically contiguous, as long as it functions as an integrated department of that hospital. Senator Roberts, the bill's sponsor, described the team trying "every possible way" to make the facility eligible before concluding legislation was necessary. The bill passed 6-0.
The Pharmacy Wars Come to Colorado
The most contested bill of the two-day stretch was HB 26-1262, the Colorado Patient Access and Compounding Clarity Act — a bill born from a legal fight that started in California and Texas and hasn't yet reached Colorado, but might.
Dr. Sean Pasoski, a Fort Collins neurologist presenting as president-elect of the Colorado Medical Society, made the medical case for why compounded medications — drugs custom-prepared by pharmacists rather than mass-manufactured — are not a niche concern. "Standard commercially manufactured medications in their standard dosages and standard forms does not work for everyone," he testified. "A child who cannot swallow a tablet, a surgical patient who needs an exact concentration not sold commercially, a hospice patient whose comfort depends on a formulation that no manufacturer produces. These are not edge cases. They are the patients that we see every day in Colorado hospitals, clinics and doctor's offices."
The bill's sponsors, Senators Ball and Roberts, argued that recent federal court decisions created legal uncertainty about whether state pharmacy rules could conflict with federal compounding standards — and that HB 26-1262 simply aligns Colorado law with existing FDA frameworks to prevent compounding pharmacies from being treated like large-scale manufacturers.
The sole opposition witness was Zoe Powers, representing Eli Lilly, and her most powerful argument came in the form of a history lesson. "In 2011, Colorado's board issued a cease and desist to the New England Compounding center after state inspectors found stock compounded drugs in Colorado hospitals without patient specific prescriptions," Powers told the committee. "One year later, NECC's contaminated injections killed over 100 patients and hospitalized 800 more. Colorado's board was ahead of the FDA, and that's exactly the kind of independent state action this bill would prevent."
The reference to the 2012 NECC meningitis outbreak — one of the deadliest compounding pharmacy disasters in American history — landed with force. Powers also argued that the FDA draft guidance underlying the bill "hasn't been finalized" and "carries no force of law," and that FDA staff was already looking to revise it in 2026.
Senator Weissman pressed Senator Ball directly on the legal logic: if the Fifth Circuit had largely repudiated the lower court's reasoning in the key litigation, what exactly was the bill protecting against? Ball's answer was honest about the uncertainty: the 10th Circuit — which covers Colorado — hasn't ruled yet, and a similar challenge could emerge in Colorado's federal district courts. The bill, he argued, is about "preserving the status quo" rather than expanding anything.
In direct response to Powers's testimony, Ball offered Amendment L7, which exempted 503B outsourcing facilities from the bill's scope entirely — a targeted concession that narrowed the bill's reach to 503A retail compounding pharmacies. The committee passed the amended bill 6-0.
Medicaid's New Sheriff
Before any of the bills were heard on April 8, the committee had a different order of business: confirming Gretchen Hammer as the new Executive Director of the Department of Healthcare Policy and Financing, the state agency that administers Medicaid and Child Health Plan Plus for over a million Coloradans.
The confirmation was unanimous — 7-0 — but the hearing was anything but perfunctory. Senator Frizell cited a damning audit record: 121 total audit recommendations for HCPF between 2019 and 2024, the third-highest of any state department, with 11 still unimplemented — some outstanding for up to 49 months. Senator Weissman challenged Hammer to build systems capable of detecting private interests capturing Medicaid dollars. Chair Mullica cited a $650 transport reimbursement that should have been $65.
Hammer didn't deflect. "We need to be accountable," she told the committee. "These resources are finite. And to the extent we are not, we could crowd out other public priorities." She committed to reviewing the 11 outstanding audit recommendations within her first two weeks in the role.
David Oppenheim, Chief of Staff for Governor Polis, introduced Hammer by acknowledging the Governor is "under no illusion about the moment this department finds itself in" — a striking admission of institutional fragility from an administration official at a confirmation hearing.
The Stakes
Across these five bills and one confirmation hearing, Colorado's legislature is attempting something ambitious: not a single sweeping reform, but a methodical series of fixes to a system that's been quietly breaking in dozens of places at once.
If SB 26-006 passes and reaches the governor's desk, Coloradans with private insurance will have a new legal right to access non-opioid pain medications without extra bureaucratic hurdles — though Medicaid patients, for now, are left out. If HB 26-1019 becomes law, insured Coloradans will be able to get annual kidney screenings at no cost, potentially catching a disease that Senator Roberts noted afflicts one in seven adults before it becomes irreversible and ruinously expensive. If HB 26-1305 is signed, the only inpatient psychiatric facility between Denver and Salt Lake City can finally take Medicaid patients without burning millions of dollars in unnecessary administrative overhead.
And if the compounding pharmacy bill survives its path through the full Senate and then the House — and survives whatever the 10th Circuit eventually decides — the patients Dr. Pasoski described will keep getting the medications that only exist because a pharmacist made them by hand.
For the million-plus Coloradans who depend on HCPF, the most consequential action of the week may have been the quietest: a unanimous vote to put a new executive director in charge of a department with 11 unfinished audit recommendations and a history of paying 10 times what it should for a ride to the doctor. Gretchen Hammer has two weeks to start fixing it. The committee will be watching.